84 related articles for article (PubMed ID: 30511892)
21. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables.
Kamalakaran S; Varadan V; Giercksky Russnes HE; Levy D; Kendall J; Janevski A; Riggs M; Banerjee N; Synnestvedt M; Schlichting E; Kåresen R; Shama Prasada K; Rotti H; Rao R; Rao L; Eric Tang MH; Satyamoorthy K; Lucito R; Wigler M; Dimitrova N; Naume B; Borresen-Dale AL; Hicks JB
Mol Oncol; 2011 Feb; 5(1):77-92. PubMed ID: 21169070
[TBL] [Abstract][Full Text] [Related]
22. Mining Prognostic Significance of MEG3 in Human Breast Cancer Using Bioinformatics Analysis.
Cui X; Yi Q; Jing X; Huang Y; Tian J; Long C; Xiang Z; Liu J; Zhang C; Tan B; Li Y; Zhu J
Cell Physiol Biochem; 2018; 50(1):41-51. PubMed ID: 30278461
[TBL] [Abstract][Full Text] [Related]
23. [Relationship of c-FLIP(L) protein expression with molecular subtyping and clinical prognosis in invasive breast cancer].
Zang F; Wei X; Sun B
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):442-6. PubMed ID: 25327791
[TBL] [Abstract][Full Text] [Related]
24. HOXD13 methylation status is a prognostic indicator in breast cancer.
Zhong Z; Shan M; Wang J; Liu T; Xia B; Niu M; Ren Y; Pang D
Int J Clin Exp Pathol; 2015; 8(9):10716-24. PubMed ID: 26617782
[TBL] [Abstract][Full Text] [Related]
25. Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer.
van Hoesel AQ; van de Velde CJ; Kuppen PJ; Putter H; de Kruijf EM; van Nes JG; Giuliano AE; Hoon DS
Breast Cancer Res Treat; 2012 Feb; 131(3):859-69. PubMed ID: 21479925
[TBL] [Abstract][Full Text] [Related]
26. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
27. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells.
Mahauad-Fernandez WD; Borcherding NC; Zhang W; Okeoma CM
PLoS One; 2015; 10(4):e0123931. PubMed ID: 25860442
[TBL] [Abstract][Full Text] [Related]
29. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
30. Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.
Tishchenko I; Milioli HH; Riveros C; Moscato P
PLoS One; 2016; 11(6):e0158259. PubMed ID: 27341628
[TBL] [Abstract][Full Text] [Related]
31. CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer.
Sim SH; Bae CD; Kwon Y; Hwang HL; Poojan S; Hong HI; Kim K; Kang SH; Kim HS; Um TH; Park IH; Lee KS; Jung SY; Lee S; Kang HS; Lee ES; Kim MK; Hong KM; Ro J
PLoS One; 2017; 12(8):e0182107. PubMed ID: 28771517
[TBL] [Abstract][Full Text] [Related]
32. The impact of different tumour subtypes on management and survival of New Zealand women with Stage I-III breast cancer.
Lawrenson R; Lao C; Campbell I; Harvey V; Seneviratne S; Elwood M; Sarfati D; Kuper-Hommel M
N Z Med J; 2018 May; 131(1475):51-60. PubMed ID: 29771902
[TBL] [Abstract][Full Text] [Related]
33. MLF1IP is correlated with progression and prognosis in luminal breast cancer.
Huang DP; Luo RC
Biochem Biophys Res Commun; 2016 Sep; 477(4):923-926. PubMed ID: 27378428
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of immune-related markers in breast cancer by molecular phenotypes.
Choi J; Kim DH; Jung WH; Koo JS
Breast Cancer Res Treat; 2013 Jan; 137(2):417-29. PubMed ID: 23242618
[TBL] [Abstract][Full Text] [Related]
36. Enabled homolog shown to be a potential biomarker and prognostic indicator for breast cancer by bioinformatics analysis.
Li QL; Su YL; Zeng M; Shen WX
Clin Invest Med; 2019 Jan; 41(4):E186-E195. PubMed ID: 30737978
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
38. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
[TBL] [Abstract][Full Text] [Related]
39. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
Li JY; Jia S; Zhang WH; Zhang Y; Kang Y; Li PS
Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
[TBL] [Abstract][Full Text] [Related]
40. The prognostic value of lymph node status among breast cancer subtypes.
Liao GS; Chou YC; Hsu HM; Dai MS; Yu JC
Am J Surg; 2015 Apr; 209(4):717-24. PubMed ID: 25192588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]